First-Line Combination Immunotherapy and Management of HCV Cirrhosis-Associated Metastatic HCC
First-Line Combination Immunotherapy and Management of HCV Cirrhosis-Associated Metastatic HCC is organized by Projects In Knowledge Inc.
Release Date: Apr 05, 2023
Termination Date: Apr 04, 2024
Activity Goal:
The goal of this program is to provide data from medical meetings, expert analysis insights on current and emerging management strategies, and interactive case studies based on the most up-to-date evidence-based medicine and clinical trial results in HCC.
Learning Objective(s):
• Employ patient-centered strategies for the first-line treatment of hepatitis C virus cirrhosis-associated metastatic hepatocellular carcinoma (HCC).
• Summarize key data on atezolizumab plus bevacizumab and tremelimumab plus durvalumab in the evolving landscape of treatment for patients with metastatic HCC.
Additional details will be posted as soon as information is available